FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Muscle Res Cell Motil / Therapeutic clenbuterol treatment does not alter Ca2+ sensit...
Journal of muscle research and cell motility2003; 24(7); 471-476; doi: 10.1023/a:1027377731137

Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses.

Abstract: Clenbuterol is a beta2-adrenoceptor agonist primarily used for treating bronchospasm and alleviating the symptoms of chronic obstructive pulmonary disease (COPD) in the horse. In other species (rats, mice, sheep, and cattle), chronic high doses of clenbuterol (typically in the milligram per kilogram body weight range) has been shown to cause a muscle directed protein anabolic response. Clenbuterol can also modify muscle fibre composition and therefore potentially affect muscle function. This has implications for the performance of exercising horses being treated with therapeutic doses of clenbuterol (typically in the microgram per kilogram body weight range) for bronchospasm or COPD. It is not known whether clenbuterol treatment affects muscle fibre function in horses. The purpose of this study was to examine the effects of a therapeutic dose of clenbuterol, with and without exercise, on the contractile activation characteristics of single membrane permeabilized fibres prepared from muscle biopsies. We tested the hypothesis that therapeutic treatment with clenbuterol would not affect muscle fibre function. Unfit Standardbred mares were treated for 8 weeks with; clenbuterol (2.4 microg/kg twice/day, 5 days/week) plus exercise (20 min at 50% VO2(max) 3 d/wk; CLENEX), clenbuterol only (CLEN), or exercise only (EX). Muscle biopsies were taken from the gluteus medius muscle before and after treatment and stored in a glycerol-based solution to prepare permeabilized muscle fibres. The force-pCa relationship for fibres from CLEN horses was steeper (P < 0.05) indicative of greater cooperative interactions within the thin filament, however, fibre sensitivity to Ca2+ was unchanged. In contrast, the steepness of the force-pCa relationship was not changed in fibres from EX and CLENEX horses and Ca2+ sensitivity was also unaffected. Rigor force, activation in the absence of ATP, was not affected by any treatment indicating an approximately equivalent number of participating cross-bridges during activation. The results indicate that a therapeutic dose of clenbuterol to Standardbred horses does not affect the Ca(2+)-activated contractile characteristics of isolated muscle fibres.
Get Full Text
Publication Date: 2003-12-18 PubMed ID: 14677650DOI: 10.1023/a:1027377731137Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article investigates whether a therapeutic dose of clenbuterol, a medication primarily used to treat breathing disorders in horses, affects the function of muscle fibres in these animals, both with and without exercise. The findings show that the medication, in therapeutic amounts, does not alter calcium-activated contractile characteristics in the muscle fibres of these horses.

Objective of the Research

The study seeks to understand the impact of clenbuterol on muscle fibre function in horses. Clenbuterol, a beta2-adrenoceptor agonist, has been shown in other species to cause an anabolic response in muscles with high doses. This could potentially impact muscle composition and function, affecting the performance of horses treated with the medication for bronchospasm or chronic obstructive pulmonary disease (COPD). Considering these implications, the researchers hypothesize that therapeutic doses of clenbuterol would not affect the function of the muscle fibres of horses.

  • The therapeutic dosage used was 2.4 micrograms/kg twice per day, five days a week, over an eight-week period.
  • The study also considered the potential impact of exercise on the outcomes, utilizing a regimen of 20 minutes at 50% VO2max, three times per week.
  • Muscle biopsies, taken from the gluteus medius muscle before and after treatment, were used to examine the impact on muscle fibres.

Findings of the Research

The study found that therapeutic doses of clenbuterol do not impact the calcium-activated contractile characteristics of horse muscle fibres.

  • In horses treated solely with clenbuterol (CLEN group), the force and calcium relationship was steeper, indicating more cooperative interactions within the thin filament. However, fibre sensitivity to calcium remained unchanged.
  • Contrastingly, in horses treated with clenbuterol and subjected to exercise (CLENEX group), as well as those subjected to exercise alone (EX group), the steepness of the force and calcium relationship exhibited no change. Similarly, calcium sensitivity also remained unchanged.
  • In all groups, rigor force, activation in the absence of ATP, remained unaffected. This suggests an approximately equivalent number of participating cross-bridges during activation.

Conclusion of the Research

These findings led the researchers to conclude that therapeutic doses of clenbuterol do not affect the calcium-activated contractile characteristics of muscle fibres in horses. This suggests that the administration of clenbuterol for bronchospasm or COPD treatment wouldn’t adversely impact the muscle performance of horses.

Cite This Article

APA
Plant DR, Kearns CF, McKeever KH, Lynch GS. (2003). Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses. J Muscle Res Cell Motil, 24(7), 471-476. https://doi.org/10.1023/a:1027377731137

Publication

Journal of muscle research and cell motility
ISSN: 0142-4319
NlmUniqueID: 8006298
Country: Netherlands
Language: English
Volume: 24
Issue: 7
Pages: 471-476

Researcher Affiliations

Plant, David R
  • Department of Physiology, The University of Melbourne, Victoria 3010, Australia.
Kearns, Charles F
    McKeever, Kenneth H
      Lynch, Gordon S

        MeSH Terms

        • Adrenergic beta-Agonists / pharmacology
        • Animals
        • Calcium / metabolism
        • Clenbuterol / pharmacology
        • Horses / metabolism
        • Horses / physiology
        • Male
        • Muscle Contraction / physiology
        • Muscle Fibers, Skeletal / drug effects
        • Muscle Fibers, Skeletal / metabolism
        • Muscle Fibers, Skeletal / physiology
        • Muscle, Skeletal / drug effects
        • Muscle, Skeletal / metabolism
        • Muscle, Skeletal / physiology
        • Physical Conditioning, Animal

        References

        This article includes 31 references
        1. Zeman RJ, Ludemann R, Easton TG, Etlinger JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist.. Am J Physiol 1988 Jun;254(6 Pt 1):E726-32.
          pubmed: 3377073doi: 10.1152/ajpendo.1988.254.6.E726google scholar: lookup
        2. Lynch GS, Hayes A, Campbell SP, Williams DA. Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers.. J Appl Physiol (1985) 1996 Oct;81(4):1610-8.
          pubmed: 8904577doi: 10.1152/jappl.1996.81.4.1610google scholar: lookup
        3. Duncan ND, Williams DA, Lynch GS. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats.. Clin Sci (Lond) 2000 Mar;98(3):339-47.
          pubmed: 10677393
        4. Plant DR, Lynch GS, Williams DA. Hydrogen peroxide modulates Ca2+-activation of single permeabilized fibres from fast- and slow-twitch skeletal muscles of rats.. J Muscle Res Cell Motil 2000;21(8):747-52.
          pubmed: 11392556doi: 10.1023/a:1010344008224google scholar: lookup
        5. Brandt PW, Diamond MS, Schachat FH. The thin filament of vertebrate skeletal muscle co-operatively activates as a unit.. J Mol Biol 1984 Dec 5;180(2):379-84.
          pubmed: 6542594doi: 10.1016/s0022-2836(84)80010-8google scholar: lookup
        6. Chen KD, Alway SE. A physiological level of clenbuterol does not prevent atrophy or loss of force in skeletal muscle of old rats.. J Appl Physiol (1985) 2000 Aug;89(2):606-12.
          pubmed: 10926644doi: 10.1152/jappl.2000.89.2.606google scholar: lookup
        7. Bortolotto SK, Cellini M, Stephenson DG, Stephenson GM. MHC isoform composition and Ca(2+)- or Sr(2+)-activation properties of rat skeletal muscle fibers.. Am J Physiol Cell Physiol 2000 Nov;279(5):C1564-77.
          pubmed: 11029304doi: 10.1152/ajpcell.2000.279.5.C1564google scholar: lookup
        8. Gordon AM, Homsher E, Regnier M. Regulation of contraction in striated muscle.. Physiol Rev 2000 Apr;80(2):853-924.
          pubmed: 10747208doi: 10.1152/physrev.2000.80.2.853google scholar: lookup
        9. Rivero JL, Talmadge RJ, Edgerton VR. Myosin heavy chain isoforms in adult equine skeletal muscle: an immunohistochemical and electrophoretic study.. Anat Rec 1996 Oct;246(2):185-94.
          pubmed: 8888960doi: 10.1002/(SICI)1097-0185(199610)246:2<185::AID-AR5>3.0.CO;2-0google scholar: lookup
        10. Gregorevic P, Williams DA, Lynch GS. Effects of leukemia inhibitory factor on rat skeletal muscles are modulated by clenbuterol.. Muscle Nerve 2002 Feb;25(2):194-201.
          pubmed: 11870686doi: 10.1002/mus.10015google scholar: lookup
        11. Moisescu DG. Kinetics of reaction in calcium-activated skinned muscle fibres.. Nature 1976 Aug 12;262(5569):610-3.
          pubmed: 958428doi: 10.1038/262610a0google scholar: lookup
        12. Choo JJ, Horan MA, Little RA, Rothwell NJ. Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation.. Am J Physiol 1992 Jul;263(1 Pt 1):E50-6.
          pubmed: 1322047doi: 10.1152/ajpendo.1992.263.1.E50google scholar: lookup
        13. Lynch GS, Stephenson DG, Williams DA. Analysis of Ca2+ and Sr2+ activation characteristics in skinned muscle fibre preparations with different proportions of myofibrillar isoforms.. J Muscle Res Cell Motil 1995 Feb;16(1):65-78.
          pubmed: 7751406doi: 10.1007/BF00125311google scholar: lookup
        14. Campbell KS, Moss RL. History-dependent mechanical properties of permeabilized rat soleus muscle fibers.. Biophys J 2002 Feb;82(2):929-43.
          pubmed: 11806934doi: 10.1016/S0006-3495(02)75454-4google scholar: lookup
        15. Regnier M, Rivera AJ, Wang CK, Bates MA, Chase PB, Gordon AM. Thin filament near-neighbour regulatory unit interactions affect rabbit skeletal muscle steady-state force-Ca(2+) relations.. J Physiol 2002 Apr 15;540(Pt 2):485-97.
          pubmed: 11956338doi: 10.1113/jphysiol.2001.013179google scholar: lookup
        16. Emery PW, Rothwell NJ, Stock MJ, Winter PD. Chronic effects of beta 2-adrenergic agonists on body composition and protein synthesis in the rat.. Biosci Rep 1984 Jan;4(1):83-91.
          pubmed: 6141823doi: 10.1007/BF01120827google scholar: lookup
        17. Ryall JG, Gregorevic P, Plant DR, Sillence MN, Lynch GS. Beta 2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol.. Am J Physiol Regul Integr Comp Physiol 2002 Dec;283(6):R1386-94.
          pubmed: 12388476doi: 10.1152/ajpregu.00324.2002google scholar: lookup
        18. Serrano AL, Petrie JL, Rivero JL, Hermanson JW. Myosin isoforms and muscle fiber characteristics in equine gluteus medius muscle.. Anat Rec 1996 Apr;244(4):444-51.
          pubmed: 8694280doi: 10.1002/(SICI)1097-0185(199604)244:4<444::AID-AR3>3.0.CO;2-Vgoogle scholar: lookup
        19. Ingalls CP, Barnes WS, Smith SB. Interaction between clenbuterol and run training: effects on exercise performance and MLC isoform content.. J Appl Physiol (1985) 1996 Mar;80(3):795-801.
          pubmed: 8964739doi: 10.1152/jappl.1996.80.3.795google scholar: lookup
        20. Smith WN, Dirks A, Sugiura T, Muller S, Scarpace P, Powers SK. Alteration of contractile force and mass in the senescent diaphragm with beta(2)-agonist treatment.. J Appl Physiol (1985) 2002 Mar;92(3):941-8.
          pubmed: 11842024doi: 10.1152/japplphysiol.00576.2001google scholar: lookup
        21. Erichsen DF, Aviad AD, Schultz RH, Kennedy TJ. Clinical efficacy and safety of clenbuterol HCl when administered to effect in horses with chronic obstructive pulmonary disease (COPD).. Equine Vet J 1994 Jul;26(4):331-6.
          pubmed: 8575403doi: 10.1111/j.2042-3306.1994.tb04396.xgoogle scholar: lookup
        22. Torgan CE, Etgen GJ Jr, Kang HY, Ivy JL. Fiber type-specific effects of clenbuterol and exercise training on insulin-resistant muscle.. J Appl Physiol (1985) 1995 Jul;79(1):163-7.
          pubmed: 7559215doi: 10.1152/jappl.1995.79.1.163google scholar: lookup
        23. Stephenson DG, Williams DA. Effects of sarcomere length on the force-pCa relation in fast- and slow-twitch skinned muscle fibres from the rat.. J Physiol 1982 Dec;333:637-53.
          pubmed: 7182478doi: 10.1113/jphysiol.1982.sp014473google scholar: lookup
        24. Plant DR, Lynch GS. Rigor force responses of permeabilized fibres from fast and slow skeletal muscles of aged rats.. Clin Exp Pharmacol Physiol 2001 Sep;28(9):779-81.
          pubmed: 11553038doi: 10.1046/j.1440-1681.2001.03521.xgoogle scholar: lookup
        25. MacLennan PA, Edwards RH. Effects of clenbuterol and propranolol on muscle mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy.. Biochem J 1989 Dec 1;264(2):573-9.
          pubmed: 2481447doi: 10.1042/bj2640573google scholar: lookup
        26. Fink RH, Stephenson DG, Williams DA. Potassium and ionic strength effects on the isometric force of skinned twitch muscle fibres of the rat and toad.. J Physiol 1986 Jan;370:317-37.
          pubmed: 3083099doi: 10.1113/jphysiol.1986.sp015937google scholar: lookup
        27. Claeys MC, Mulvaney DR, McCarthy FD, Gore MT, Marple DN, Sartin JL. Skeletal muscle protein synthesis and growth hormone secretion in young lambs treated with clenbuterol.. J Anim Sci 1989 Sep;67(9):2245-54.
          pubmed: 2599974doi: 10.2527/jas1989.6792245xgoogle scholar: lookup
        28. Sleeper MM, Kearns CF, McKeever KH. Chronic clenbuterol administration negatively alters cardiac function.. Med Sci Sports Exerc 2002 Apr;34(4):643-50.
          pubmed: 11932573doi: 10.1097/00005768-200204000-00013google scholar: lookup
        29. Kearns CF, McKeever KH, Malinowski K, Struck MB, Abe T. Chronic administration of therapeutic levels of clenbuterol acts as a repartitioning agent.. J Appl Physiol (1985) 2001 Nov;91(5):2064-70.
          pubmed: 11641345doi: 10.1152/jappl.2001.91.5.2064google scholar: lookup
        30. Rose RJ, Allen JR, Brock KA, Clark CR, Hodgson DR, Stewart JH. Effects of clenbuterol hydrochloride on certain respiratory and cardiovascular parameters in horses performing treadmill exercise.. Res Vet Sci 1983 Nov;35(3):301-5.
          pubmed: 6665313
        31. Bremel RD, Weber A. Cooperation within actin filament in vertebrate skeletal muscle.. Nat New Biol 1972 Jul 26;238(82):97-101.
          pubmed: 4261616doi: 10.1038/newbio238097a0google scholar: lookup

        Citations

        This article has been cited 5 times.
        1. Ohnuki Y, Umeki D, Mototani Y, Shiozawa K, Nariyama M, Ito A, Kawamura N, Yagisawa Y, Jin H, Cai W, Suita K, Saeki Y, Fujita T, Ishikawa Y, Okumura S. Role of phosphodiesterase 4 expression in the Epac1 signaling-dependent skeletal muscle hypertrophic action of clenbuterol. Physiol Rep 2016 May;4(10).
          doi: 10.14814/phy2.12791pubmed: 27207782google scholar: lookup
        2. Koeberl DD, Li S, Dai J, Thurberg BL, Bali D, Kishnani PS. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab 2012 Feb;105(2):221-7.
          doi: 10.1016/j.ymgme.2011.11.005pubmed: 22154081google scholar: lookup
        3. Koeberl DD, Luo X, Sun B, McVie-Wylie A, Dai J, Li S, Banugaria SG, Chen YT, Bali DS. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab 2011 Jun;103(2):107-12.
          doi: 10.1016/j.ymgme.2011.02.006pubmed: 21397538google scholar: lookup
        4. Zhang J, He Q, Liu QY, Guo W, Deng XM, Zhang WW, Hu XX, Li N. Differential gene expression profile in pig adipose tissue treated with/without clenbuterol. BMC Genomics 2007 Nov 26;8:433.
          doi: 10.1186/1471-2164-8-433pubmed: 18039366google scholar: lookup
        5. Kataveni S, Gourishetty RP, Mundada SM, Avvaru MP, Kollipara VS, Gottimukkala SP. Clenbuterol Abuse in Bodybuilding and Athletics: Unsupervised Use, Psychological Motivations, and Health Consequences. Cureus 2025 May;17(5):e84904.
          doi: 10.7759/cureus.84904pubmed: 40575216google scholar: lookup
        Subscribe to our newsletter
        Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.